Latest news with #Teleflex
Yahoo
a day ago
- Business
- Yahoo
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
VALENCIA, Calif., June 04, 2025--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built around scaling disruptive MedTech platforms, Binney brings over two decades of commercial leadership experience that will be instrumental to SetPoint's mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis (RA). "Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets," said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. "His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform." With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex. "What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking," said Tyler Binney. "This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology." About SetPoint Medical SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit View source version on Contacts Emma YangHealth+Commercemedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business
- Business Wire
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
VALENCIA, Calif.--(BUSINESS WIRE)-- SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built around scaling disruptive MedTech platforms, Binney brings over two decades of commercial leadership experience that will be instrumental to SetPoint's mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis (RA). 'Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets,' said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. 'His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform.' With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex. 'What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking,' said Tyler Binney. 'This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology.' About SetPoint Medical SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit
Associated Press
19-05-2025
- Business
- Associated Press
Teleflex Publishes 2024 Global Impact Report
WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). 'This year's Global Impact Report is a demonstration of Teleflex's continued journey in Corporate Social Responsibility, evident in both the progress we have made and in our targets that we continue to set and work toward' said Cam Hicks, Corporate Vice President and Chief Human Resources Officer. 'As the Chair of our CSR Steering Committee, it's an honor to watch our CSR program continue to grow in recognition among our stakeholders and to see the pride it brings to our employees, who believe in working for a company that genuinely cares about its impact to our planet, our products and our people.' The 2024 Global Impact Report outlines accomplishments and plans for each of the company's four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance. Highlights from this year's report include: Read the full 2024 Global Impact Report at About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.© 2025 Teleflex Incorporated. All rights reserved. Contacts: Teleflex Lawrence Keusch Vice President, Investor Relations and Strategy Development [email protected] 610-948-2836
Yahoo
19-05-2025
- Business
- Yahoo
Teleflex Publishes 2024 Global Impact Report
Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). 'This year's Global Impact Report is a demonstration of Teleflex's continued journey in Corporate Social Responsibility, evident in both the progress we have made and in our targets that we continue to set and work toward' said Cam Hicks, Corporate Vice President and Chief Human Resources Officer. 'As the Chair of our CSR Steering Committee, it's an honor to watch our CSR program continue to grow in recognition among our stakeholders and to see the pride it brings to our employees, who believe in working for a company that genuinely cares about its impact to our planet, our products and our people.' The 2024 Global Impact Report outlines accomplishments and plans for each of the company's four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance. Highlights from this year's report include: Materiality Assessment: We conducted a double materiality assessment in line with the E.U. Corporate Sustainability Reporting Directive. This assessment determines what Teleflex will have to disclose to the E.U. Commission and gives us an opportunity to ensure our CSR strategy and focus areas remain appropriate. World Economic Forum: Teleflex signed on to the World Economic Forum Zero Health Gaps Pledge, under which Teleflex has committed to ensuring equal and equitable access to healthcare. Carbon Disclosure Project: We submitted our CDP (formerly Carbon Disclosure Project) Climate Questionnaire, which contains data points pertaining to our greenhouse gas emissions, starting with our baseline year (2019) and 2023 progress against our validated Science-Based Targets. Environmental Management Systems: In 2024, we have 6 sites that were ISO 14001 certified, and we will look to add more in the future. Read the full 2024 Global Impact Report at About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.© 2025 Teleflex Incorporated. All rights reserved. Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
TFX Q1 Earnings Call: Guidance Cut and Strategic Shifts Dominate Amid Tariff Headwinds
Medical technology company Teleflex (NYSE:TFX) met Wall Street's revenue expectations in Q1 CY2025, but sales fell by 5% year on year to $700.7 million. Its non-GAAP profit of $2.91 per share was 0.9% above analysts' consensus estimates. Is now the time to buy TFX? Find out in our full research report (it's free). Revenue: $700.7 million vs analyst estimates of $699 million (5% year-on-year decline, in line) Adjusted EPS: $2.91 vs analyst estimates of $2.88 (0.9% beat) Adjusted EBITDA: $200 million vs analyst estimates of $189.4 million (28.5% margin, 5.6% beat) Adjusted EPS guidance for the full year is $13.40 at the midpoint, missing analyst estimates by 4.9% Operating Margin: 17.9%, up from -0.6% in the same quarter last year Free Cash Flow Margin: 6.2%, down from 10.1% in the same quarter last year Constant Currency Revenue fell 3.8% year on year (3.8% in the same quarter last year) Market Capitalization: $5.6 billion Teleflex's first quarter performance reflected ongoing challenges in several business lines, as management cited lower demand in its OEM and Interventional Urology segments, as well as the impact of volume-based procurement in China. CEO Liam Kelly noted that Vascular Access and Interventional product lines showed year-over-year growth, with double-digit gains in peripherally inserted central catheters (PICCs) and intra-aortic balloon pumps in the Americas. He also pointed to strong early demand for new products like the AC3 range Intra-Aortic Balloon Pump following recent FDA clearance. Looking ahead, management revised its full-year adjusted EPS guidance downward, driven by $55 million in new tariffs and persistent macroeconomic pressures on costs. CFO John Deren described multiple mitigation efforts, including optimizing the supply chain, leveraging trade exemptions, and selective pricing increases. Still, Deren acknowledged that, 'the current tariff environment is disappointing,' and said most mitigation strategies would take time to impact results, leaving near-term profitability below initial expectations. Teleflex's management addressed a mix of operational headwinds, strategic transactions, and product pipeline updates that impacted first quarter results and will influence the business going forward. OEM and UroLift Weakness: The largest revenue declines stemmed from the OEM segment due to lost customer contracts and inventory management, and continued pressure on UroLift in Interventional Urology, especially in U.S. office settings. Management expects sequential improvement in OEM orders throughout the year as contract anniversaries pass. China Procurement and Regional Volatility: Revenue in Asia fell due to volume-based procurement initiatives in China, which led to significant destocking. CEO Liam Kelly expects China and broader Asia Pacific to recover gradually in coming quarters as these effects abate. Vascular Access and Interventional Growth: Vascular Access saw double-digit growth in PICCs and continued strength in EZ-IO, while Interventional benefited from robust demand for intra-aortic balloon pumps in the Americas and new product launches like the AC3 range, which recently received FDA clearance. Product Pipeline Advancements: Management highlighted positive preliminary clinical results for the Ringer Perfusion Balloon Catheter and the expanded indication for QuikClot Control+, which increases its addressable market in the U.S. by over $150 million. Separation and M&A Activity: Teleflex is progressing with plans to separate into two companies and to acquire BIOTRONIK's Vascular Intervention business. Management reported strong inbound interest in the potential NewCo spinoff or sale, with a parallel process underway to maximize shareholder value. Teleflex's outlook for the remainder of the year is shaped by efforts to offset cost pressures, evolving product mix, and the impact of global trade policies. Tariff Headwinds and Mitigation: The company faces $55 million in tariff costs for 2025, with management pursuing mitigation strategies including supply chain reconfiguration, maximizing USMCA exemptions, and targeted price increases. CFO John Deren confirmed that most tariff impacts will be felt in the second half of the year. Product Launches and Integration: The successful launch and commercialization of new products, particularly within the Interventional business, and the integration of BIOTRONIK's portfolio are expected to support revenue growth and margin stability. Strategic Separation Process: Execution of the planned business separation, and the potential sale of NewCo, will be a major focus. Management believes this will enable more targeted growth strategies and streamlined capital allocation, but short-term disruption is possible during the transition. Patrick Wood (Morgan Stanley): Asked about OEM demand trends amid supply chain shifts and long-term focus on vascular intervention. Management expects OEM demand to improve and is prioritizing cath lab presence post-BIOTRONIK acquisition. Michael Sarcone (Jefferies): Probed on timing and effectiveness of tariff mitigation strategies. CFO John Deren detailed actions underway but stressed most benefits will take time to materialize. Jayson Bedford (Raymond James): Inquired if Teleflex would consider selling parts of NewCo or only the entire business. CEO Liam Kelly said all options are being evaluated to maximize shareholder value. Craig Bijou (Bank of America): Sought updates on Interventional Urology—specifically UroLift and Palette performance. Management confirmed Palette's strong double-digit growth and ongoing UroLift headwinds, especially in the U.S. Anthony Petrone (Mizuho): Requested details on BIOTRONIK integration and expected revenue synergies. CEO Liam Kelly emphasized leveraging complementary sales channels in the Americas and EMEA, and highlighted R&D and clinical trial opportunities. In the next few quarters, the StockStory team will monitor (1) the pace of OEM and China business recovery as contract and procurement headwinds subside, (2) the impact and effectiveness of tariff mitigation strategies on margins, and (3) the BIOTRONIK acquisition's integration progress and new product commercialization. Execution of the proposed business separation and clarity on the outcome of the NewCo sale or spin-off process will also be key focus areas. Teleflex currently trades at a forward P/E ratio of 8.6×. Should you double down or take your chips? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
